DGAP-Adhoc: Changeover at aap Implantate AG: Bruke Seyoum Alemu appointed as new CEO

        Print
| Source: EQS Group AG
aap Implantate AG  / Key word(s): Change of Personnel/Agreement

28.04.2014 23:07

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------


Ongoing transformation to a leading trauma company keeping management
continuity


aap Implantate AG announces that its Supervisory Board named Bruke Seyoum
Alemu, 48, Chief Operating Officer of aap Implantate AG since 2008, as the
company's new chairman of the Management Board and Chief Executive Officer
(CEO), effective as of June 1, 2014.
 
With today's successful completion of the sale of aap's Dutch subsidiary
EMCM B.V., which is a consistent step in the strategy implementation
towards a focused trauma company, the Supervisory Board in consultation
with the Management Board has agreed to reduce the size of aap's Management
Board from three to two members. In view of the above, current CEO Biense
Visser and the Supervisory Board have agreed to terminate Mr. Visser's
Management Board contract prematurely as of May 31st, 2014.

To maintain continuity, Mr. Visser is prepared to serve on aap Implantate
AG's Supervisory Board provided that the necessary legal requirements are
fulfilled. The company assumes that its majority shareholders will support
Mr. Visser's move to the Supervisory Board and nominate him accordingly on
the occasion of the upcoming annual shareholders meeting.

In a separate press release aap will report in detail regarding this
change.

__________________________________________________________________________
________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market -
All German stock markets -

About aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany
that develops, manufactures and markets innovative biomaterials and
implants that are used in orthopedic procedures. The Company's products,
which include a full line of plating systems, cannulated screws and bone
cement products, are primarily used in the orthopedic specialty areas of
trauma and spine repair. The Company's products are sold through its direct
sales force, distribution partners and license agreements with OEM
partners. aap's stock is listed in the Prime Standard segment of the
Frankfurt Stock Exchange. For more information, please visit www.aap.de, or
download the Company's investor relations app from the Apple's App Store or
Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. Many factors could cause the actual results, performance or
achievements of aap to be materially different from those that may be
expressed or implied by such statements. These factors include those
discussed in aap's public reports. Forward-looking statements therefore
speak only as of the date they are made. aap does not assume any obligation
to update the forward-looking statements contained in this release or to
conform them to future events or developments.
 
For inquiries please contact: aap Implantate AG, Marc Heydrich, Investor
Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap.de


28.04.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      aap Implantate AG
              Lorenzweg 5
              12099 Berlin
              Germany
Phone:        +49 (0) 30 75 01 90
Fax:          +49 (0) 30 75 01 91 11
E-mail:       info@aap.de
Internet:     www.aap.de
ISIN:         DE0005066609
WKN:          506660
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------